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ABSTRACT
Objective Amyotrophic lateral sclerosis (ALS) is a 
rapidly progressive neurodegenerative disease of motor 
neurons with a median survival of 2 years. Familial ALS 
has a younger age of onset than apparently sporadic 
ALS. We sought to determine whether this younger age 
of onset is a result of ascertainment bias or has a genetic 
basis.
Methods Samples from people with ALS were 
sequenced for 13 ALS genes. To determine the effect of 
genetic variation, age of onset was compared in people 
with sporadic ALS carrying a pathogenic gene variant 
and those who do not; to determine the effect of family 
history, we compared those with genetic sporadic ALS 
and familial ALS.
Results There were 941 people with a diagnosis of ALS, 
100 with familial ALS. Of 841 with apparently sporadic 
ALS, 95 carried a pathogenic gene variant. The mean 
age of onset in familial ALS was 5.3 years younger than 
for apparently sporadic ALS (p=6.0×10−5, 95% CI 2.8 
to 7.8 years). The mean age of onset of genetic sporadic 
ALS was 2.9 years younger than non-genetic sporadic 
ALS (p=0.011, 95% CI 0.7 to 5.2 years). There was no 
difference between the mean age of onset in genetic 
sporadic ALS and familial ALS (p=0.097).
Conclusions People with familial ALS have an age of 
onset about 5 years younger than those with apparently 
sporadic ALS, and we have shown that this is a result 
of Mendelian gene variants lowering the age of onset, 
rather than ascertainment bias.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS), also known 
as motor neuron disease, is a rapidly progressive 
and paralysing illness resulting from degeneration 
of upper and lower motor neurons; it has no cure 
and the median survival is 2 years.1 The mean age 
of onset in clinic populations is about 58 years,2 
and in population studies about 64,3 but it can 
affect people of any age.
The age of onset of people with familial ALS is 
widely reported as being about 10 years younger 
than for those with apparently sporadic ALS.46 
This may be a result of the greater awareness of 
those who have already experienced ALS in their 
family, leading them to seek medical attention 
sooner, and the greater likelihood of recognition 
of the diagnosis by medical professionals when 
there is an existing family history. Such ascertain-
ment bias has been proposed as the mechanism for 
the genetic phenomenon of anticipation, in which 
genetic diseases seem to occur at younger ages in 
succeeding generations.7 Another explanation, 
however, is that large-effect Mendelian ALS genes 
themselves lower the disease age of onset. Studies 
aiming to investigate genetic factors that influence 
ALS phenotypes, including age of onset, have yet 
to yield replicable positive results.8
Familial ALS has been described since the 
mid-1800s, and the rate is reported as 5%,9 
10%10 or as high as 20%.11 The reasons for the 
discrepancy probably relate, at least in part, 
to differing personal definitions of a positive 
family history.12 People with ALS but without a 
family history are described as having sporadic 
or isolated ALS. Sporadic ALS is sometimes 
conflated with non-genetic ALS, but familial ALS 
may be missed, for example, because of the uncer-
tainty around what should constitute a relevant 
family history, and apparently sporadic ALS may 
sometimes result from large-effect, rare, Mende-
lian gene variants.1315 The result is that there are 
three genetic groups of people with ALS: those 
with a family history of disease (group 1), those 
with no family history but a known genetic cause 
(group 2), and those with no family history and 
no known genetic cause (group 3). The relative 
age of onset would be expected to differ between 
these groups depending on whether ascertain-
ment bias or genetic effects are driving the earlier 
onset. If ascertainment bias is the explanation for 
a younger age of onset in familial ALS, group 1 
should have a younger age of onset than group 
2, because the only difference is knowledge 
of family history (both share a genetic basis), 
whereas if genetic causes are the explanation, 
group 2 should have a younger age of onset than 
group 3, because the only difference is a genetic 
basis of the disease (in both there is no known 
family history).
We therefore sought to determine whether 
the younger age of onset observed in those with 
familial ALS is a result of ascertainment bias.
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Table 1 Mutations identiied in those with familial amyotrophic 
lateral sclerosis (ALS)
Gene Variant Cases (n)
C9orf72 Expansion mutation 34
DAO p.R199W 1
FUS p.R521H 2
p.R514G 1
SOD1 p.C112Y 1
p.D91A 1
p.L107F 1
p.D102N 1
p.D102G 1
p.I114T 2
p.D77Y 2
SQSTM1 p.K238E 2
TARDBP p.N378D 2
p.A90V 1
p.M337V 1
p.G348V 1
p.Y374X 1
UBQLN2 p.P497H 1
No mutation identiied 44
Total 100
95 of the 100 familial ALS cases were tested for the C9orf72 expansion mutation.
METHODS
Data sources
Patients of European ancestry who had contributed to the UK 
National DNA Bank for Motor Neuron Disease Research were 
analysed. Age of onset and family history were obtained for each 
person.
Determination of pathogenic ALS gene variants
A panel of 13 ALS genes was tested (ANG, C9orf72, DAO, 
DCTN1, FUS, OPTN, PFN1, SOD1, SQSTM1, TARDBP, 
UBQLN2, VAPB and VCP), selected for harbouring large-ef-
fect, rare, Mendelian ALS gene variants.16 17 Pathogenicity was 
defined based on previously reported association with ALS, or 
detection in cases, but not in controls or several control data-
bases.17 Because of the rapid rate of advance of ALS genetics, 
more recently identified genes, such as TBK1, were not studied.18 
DNA was sequenced using Illumina MiSeq technology by means 
of the Illumina TruSeq Custom Amplicon Assay, as previously 
described,17 and repeat primed PCR used to assay the hexanu-
cleotide repeat expansion in the C9orf72 gene.19
Patients were classified into three groups: group 1, familial 
ALS; group 2, apparently sporadic ALS with a genetic basis; 
group 3, apparently sporadic ALS without an identified genetic 
basis.
Statistical analysis
The mean age of onset between groups was compared with a 
t-test. Uncorrected p values are reported. To estimate the size 
of any ascertainment bias observed, the median time between 
symptom onset and diagnosis was compared between those with 
familial ALS and those with apparently sporadic ALS, in a Mann-
Whitney U test. Analyses were performed in SPSS V.24.0.
RESULTS
There were 941 people with ALS included in the study, 841 
with apparently sporadic ALS and 100 with familial ALS 
(table 1). There were 95 people with apparently sporadic ALS 
with a presumed pathogenic ALS gene variant (table 2) and 746 
without.
The mean age of onset for those with familial ALS was 56.2 
years (SD 12.1), all apparently sporadic ALS 61.5 years (SD 
11.0), genetically determined apparently sporadic ALS 58.9 
years (SD 10.3) and apparently sporadic ALS without a genetic 
basis 61.8 years (SD 11.1).
The mean age of onset in familial ALS was 5.3 years younger 
than for apparently sporadic ALS (p=6.0×10ï, 95% CI for the 
difference 2.8 to 7.8 years), confirming previous observations 
that familial ALS has a younger age of onset.
There was no difference between the mean age of onset of 
people with familial ALS (group 1) and those with genetic appar-
ently sporadic ALS (group 2; p=0.097), suggesting that ascer-
tainment bias plays little role in the observed younger age of 
onset. The mean age of onset of those with genetic apparently 
sporadic ALS (group 2) was 2.9 years younger than those with 
non-genetic sporadic ALS (group 3; p=0.011, 95% CI for the 
difference 0.7 to 5.2 years), consistent with the hypothesis that 
genetic burden lowers the age of onset. Combining the genetic 
groups and comparing them with the non-genetic ALS group 
confirmed the finding, with a mean age of onset of 3.4 years 
younger for the genetic groups than the non-genetic group 
(p=2.0×10ï, 95% CI for the difference 2.5 to 6.1).
The median time between symptom onset and diagnosis was 
3 months shorter for familial ALS than apparently sporadic ALS 
(p=0.012).
DISCUSSION
We have confirmed that people with familial ALS have an age 
of onset about 5 years younger than those with apparently 
sporadic ALS, as opposed to the widely quoted 10 years, and 
we propose that this up-to-date figure obtained from a large 
data set should be used in the clinical setting, particularly 
when communicating with patients. We have shown that this 
younger age of onset in familial ALS is a result of Mende-
lian gene variants lowering the actual age of onset, rather than 
ascertainment bias resulting in quicker recognition of symp-
toms. Ascertainment bias does exist, in that people with a 
family history of ALS are diagnosed on average 3 months more 
quickly than those without, but the ascertainment bias has no 
effect on age of onset.
Our findings are consistent with recent findings in which the 
multistep model of ALS20 was applied to three known genetic 
causes of ALS: mutation in SOD1, mutation in TARDBP 
(coding for TDP43) and pathological expansion of a hexa-
nucleotide repeat in the C9orf72 gene.21 These gene variants 
account for more than one step in the pathological process 
leading to ALS, leaving fewer risk factors to encounter before 
onset and therefore making a younger age of onset more likely. 
One might also expect some genes or gene variants to show 
a characteristic spectrum of age of onset, which will become 
apparent as our genetic knowledge of ALS increases. A similar 
situation may also exist in other neurodegenerative diseases in 
which those with a family history have a younger onset than 
those without, such as Alzheimers disease and Parkinsons 
disease.
A weakness of this study is that we only ascertained a 
genetic basis for ALS using a panel of 13 genes. Even with this 
restricted set, however, we were able to show that the reduced 
age of onset is a result of Mendelian disease genes. Further-
more, it is only now, with the availability of high-throughput 
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Table 2 Mutations identiied in those with apparently sporadic 
amyotrophic lateral sclerosis
Gene Variant Cases (n)
ANG p.K78E* 2
p.R146H 1
C9orf72 Expansion mutation* 36
DAO p.R199Q 1
DCTN1 p.V1081M 1
p.T12A 1
p.R785W 1
FUS p.R269W 1
p.R521C 1
p.P431L 1
p.R521L 1
p.G507D 1
p.221_221del 1
OPTN p.R545Q 1
Exon 7/Intron 7 splice site 1
p.Q441X 1
p.E380fs 1
p.V295F 1
p.N303K 1
p.G509R 1
p.A184V* 1
p.K413fs* 1
p.R271H* 1
p.F226S 1
PFN1 p.E117D* 1
p.E117G* 1
SOD1 p.D91A 1
p.T40A* 1
p.S135G* 1
p.I114T 2
p.L9V 1
SQSTM1 p.K238E* 7
p.P392L* 2
TARDBP p.G287S* 3
p.A90V 1
UBQLN2 p.A603D 1
p.T334M 3
p.L87F 1
p.P497H 1
p.496_499del 1
VAPB p.158_159del* 7
p.M170I* 5
p.R184Q 1
VCP p.I114V 1
p.G523V 1
Total 103 variants
(95 people)
In some cases, an individual had more than one pathogenic gene variant; such 
cases are indicated by an asterisk and counted for each variant. Three of these had 
C9orf72 expansion as one of the variants.
gene sequencing, that a study like this is possible, since the 
prospect of sequencing a panel of 13 genes in more than 900 
people would not have been feasible a few years ago.
Genetic modulators of the age of ALS onset have been 
studied before,8 2227 but not replicated. The explanation for 
why these have not been replicated may be that genetic risk 
factors themselves lower the age of onset and other genetic 
variants that do not influence risk have only a limited effect on 
age of onset, making them difficult to detect, even with large 
sample sizes.
Although we have identified this genetic effect on age of 
onset using large-effect, rare variants, the liability threshold 
model of disease28 29 would suggest that all genetic contribu-
tors to ALS risk lower age of onset, even common variants that 
have a small effect on risk. In the liability threshold model, 
there is a normal distribution of the burden of genetic and 
environmental risk factors (liabilities) across the population. 
Most individuals who are unaffected will possess some degree 
of liability; however, only individuals with a burden of risk 
factors sufficient to cross a threshold develop a disease. A 
consequence of the model is that affected individuals with the 
least at-risk phenotype are also those with a higher liability 
than average, since the threshold must be higher for a low-risk 
phenotype (that is why it is low risk), and yet they still have 
sufficient burden to cross it. One of the strongest risk factors 
for ALS is increased age, and therefore younger patients must 
carry a higher burden of risk factors. Thus, genetic burden is 
likely to be higher in younger patients, and conversely the age 
of onset will be lower in those with a higher genetic burden. 
One study has shown that people with ALS harbouring variants 
in more than one gene had a disease onset 10 years earlier than 
those with variants identified in only one gene, supporting the 
idea that genetic burden influences age of onset.30
Our findings show that Mendelian gene variants are associ-
ated with a younger age of onset in ALS, regardless of family 
history. Further studies are needed to elucidate the mecha-
nisms by which this occurs.
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